MedTrace Logo

Mel vs BUCY+VP-16 Conditioning Regimen for MM Undergoing Auto-HSCT

NCT03385096 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 122

Last updated 2020-02-25

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and efficacy of Melphalan and BUCY+VP-16 myeloablative conditioning regimens in multiple myeloma undergoing autologous hematopoietic stem cell transplantation.

Conditions

  • Autologous Hematopoietic Stem Cell Transplantation
  • Conditioning
  • Multiple Myeloma

Interventions

DRUG

Busulfan (BU)

Busulfan was administered at 3.2 mg/kg/day on days -8 to -6. -7 to -4.

DRUG

Cyclophosphamide (CY)

Cyclophosphamide was administered at 60 mg/kg/day on days -5 to -4. on days -3 to -2.

DRUG

Etoposide (VP-16)

Etoposide was administered at 10 mg/kg/day on days -3 to -2. -3 to -2.

DRUG

Melphalan

Melphalan was administered at 200mg/m2 on day -2.

Sponsors & Collaborators

  • Guangzhou First People's Hospital

    collaborator OTHER

  • Zhujiang Hospital

    collaborator OTHER

  • Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

    collaborator OTHER

  • Third Affiliated Hospital, Sun Yat-Sen University

    collaborator OTHER

  • Nanfang Hospital, Southern Medical University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
14 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-01-02
Primary Completion
2020-12-31
Completion
2021-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03385096 on ClinicalTrials.gov